Kazia Therapeutics Limited Adr (KZIA)

Jul 01, 2026

BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria

Jul 01, 2026

Jun 26, 2026

Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView

Jun 26, 2026

Jun 23, 2026

Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan

Jun 23, 2026

Jun 22, 2026

ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks - TradingView

Jun 22, 2026

Jun 16, 2026

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.

Jun 16, 2026

Jun 09, 2026

KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill

Jun 09, 2026

Jun 03, 2026

Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan

Jun 03, 2026

Jun 03, 2026

Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth - The Globe and Mail

Jun 03, 2026

Jun 02, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan

Jun 02, 2026

Jun 02, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan

Jun 02, 2026

Jun 02, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan

Jun 02, 2026

Jun 02, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan

Jun 02, 2026

Jun 02, 2026

Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan

Jun 02, 2026

May 30, 2026

KZIAKazia Therapeutics Limited ADR Options - Finviz

May 30, 2026

May 27, 2026

Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan

May 27, 2026

May 26, 2026

Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan

May 26, 2026

May 26, 2026

Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan

May 26, 2026

May 26, 2026

Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan

May 26, 2026

May 26, 2026

Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA) - Stock Titan

May 26, 2026

May 26, 2026

Kazia expands paxalisib trial enrollment to 36 patients in TNBC - Investing.com

May 26, 2026

May 22, 2026

KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill

May 22, 2026

May 19, 2026

Kazia Therapeutics (KZIA) Chief Scientific Officer Sudha Rao files initial Form 3 - Stock Titan

May 19, 2026

May 10, 2026

KZIA | Kazia Therapeutics Limited American Insider Trading - Quiver Quantitative

May 10, 2026

May 05, 2026

KZIA SEC FilingsKazia Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan

May 05, 2026

Apr 28, 2026

How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform - Insider Monkey

Apr 28, 2026

Apr 27, 2026

Kazia (NASDAQ: KZIA) outlines cancer pipeline and runway to 2029 - Stock Titan

Apr 27, 2026

Apr 15, 2026

Dr. Sudha Rao joins Kazia Therapeutics (NASDAQ: KZIA) as part-time CSO - Stock Titan

Apr 15, 2026

Apr 15, 2026

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - The Manila Times

Apr 15, 2026

Apr 14, 2026

Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform - BioPharma APAC

Apr 14, 2026

Apr 13, 2026

Kazia Therapeutics (NASDAQ: KZIA) in-licenses SETDB1 platform, pays $1.39M - Stock Titan

Apr 13, 2026

Apr 13, 2026

Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan

Apr 13, 2026

Apr 13, 2026

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Bitget

Apr 13, 2026

Apr 13, 2026

Kazia adds AI-built cancer drug platform with lead candidate MSETC - Stock Titan

Apr 13, 2026

Apr 09, 2026

Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan

Apr 09, 2026

Apr 01, 2026

Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan

Apr 01, 2026

Mar 31, 2026

95,110 ADS supplement and director exit — Kazia (NASDAQ: KZIA) - Stock Titan

Mar 31, 2026

Mar 31, 2026

Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan

Mar 31, 2026

Mar 30, 2026

Alumni Capital exits KZIA holdings (KZIA) — 0 ADS as of Jan 30, 2026 - Stock Titan

Mar 30, 2026

Mar 30, 2026

Kazia Therapeutics (KZIA) widens loss yet amasses $69.5m cash and new ATM - Stock Titan

Mar 30, 2026

Mar 19, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan

Mar 19, 2026

Mar 19, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan

Mar 19, 2026

Mar 19, 2026

Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan

Mar 19, 2026

Mar 19, 2026

Kazia Therapeutics (KZIA) raises major cash despite $12.6m loss - Stock Titan

Mar 19, 2026

Mar 18, 2026

Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes - Stock Titan

Mar 18, 2026

Mar 18, 2026

Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3 - Stock Titan

Mar 18, 2026

Mar 18, 2026

Kazia Therapeutics (KZIA) VP discloses initial ADS option grants - Stock Titan

Mar 18, 2026

Mar 17, 2026

Kazia Therapeutics (NASDAQ: KZIA) files $200M shelf; $100M ATM with Leerink - Stock Titan

Mar 17, 2026

Mar 07, 2026

Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail

Mar 07, 2026

Feb 20, 2026

Jorey Chernett holds 12.46% of Kazia Therapeutics (KZIA) ADS - Stock Titan

Feb 20, 2026

Feb 17, 2026

Ikarian Capital discloses 5.1% Kazia Therapeutics (KZIA) ADS position - Stock Titan

Feb 17, 2026

Feb 12, 2026

Dauntless Investment trims Kazia Therapeutics (KZIA) position to negligible 0.0% - Stock Titan

Feb 12, 2026

Jan 30, 2026

Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data By Investing.com - Investing.com India

Jan 30, 2026

Jan 30, 2026

Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com UK

Jan 30, 2026

Jan 30, 2026

Experimental cancer drug targets hidden resistance driving metastasis - Stock Titan

Jan 30, 2026